CNS Pharmaceuticals

CNS Pharmaceuticals

Pharmaceuticals
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

$7.1M

Market Cap • 10/16/2026

2017

(9 years)

Founded

2019

(7 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

—

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

—

EPS

—

Market Cap

Market Cap

7,1M

EV

-12,9M

EV/Revenue

0

EV/EBITDA

0,8

EV/EBIT

0,8

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-306,3%

Total Yield

-306,3%

Payout

0%

Retained Earnings

-107,8M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

191,4%

Capex/OCF

-0,2%

SBC/OCF

—

% PPE

0,1%

% Goodwill

0%

ROE

35,3%

ROIC

—

Growth

CAGR Op. Income 5Y

6,3%

CAGR Net Income 5Y

6,1%

CAGR OCF 5Y

4%

Leverage

N.D./EBITDA

1,2

Debt/Equity

0%

Current Ratio

5,9

Quick Ratio

5,3

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium